HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Keros Therapeutics Q4 EPS $(1.09) Beats $(1.10) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.10) by 0.91 percent. This is a 263.33 percent decrease over losses of $(0.30) per share
Cowen & Co. Initiates Coverage On Keros Therapeutics with Outperform Rating
Cowen & Co. analyst Tyler Van Buren initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating.
Keros Therapeutics Presents Preclinical Data From Its KER-012 Program At The American Heart Association 2022 Scientific Sessions
Keros Therapeutics, Inc. (“Keros”) (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from
Keros Therapeutics Presents Additional Clinical Data From Its KER-012 Program And Preclinical Data From Its KER-050 Program At The American Society Of Bone And Mineral Research 2022 Annual Meeting
Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from
BTIG Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $80
BTIG analyst Julian Harrison initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Buy rating and announces Price Target of $80.
Keros Therapeutics Highlights Presentation Of Results From Preclinical Study Of RKER-012 At Pulmonary Hypertension Association International Conference And Scientific Sessions
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for
